Paul D'Agostino

Dr. Paul D'Agostino

Department of Chemistry and Food Chemistry, Technical University of Dresden, 01062 Dresden, Germany
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2010 in Marine Drugs
Verified
Journal Article
Open access
PDF file
MWMaria Wiese
Maria Wiese
PDPaul D'Agostino
Paul D'Agostino
TMTroco K. Mihali
Troco K. Mihali
MMMichelle Moffitt
Michelle Moffitt
BNBrett Neilan
Brett Neilan
Saxitoxin (STX) and its 57 analogs are a broad group of natural neurotoxic alkaloids, commonly known as the paralytic shellfish toxins (PSTs). PSTs are the causative agents of paralytic shellfish poisoning (PSP) and are mostly associated with marine dinoflagellates (eukaryotes) and freshwater cyanobacteria (prokaryotes), which form extensive blooms around the world. PST producing dinoflagellates belong to the genera Alexandrium, Gymnodinium and Pyrodinium whilst production has been identified in several cyanobacterial genera including Anabaena, Cylindrospermopsis, Aphanizomenon Planktothrix and Lyngbya. STX and its analogs can be structurally classified into several classes such as non-sulfated, mono-sulfated, di-sulfated, decarbamoylated and the recently discovered hydrophobic analogs—each with varying levels of toxicity. Biotransformation of the PSTs into other PST analogs has been identified within marine invertebrates, humans and bacteria. An improved understanding of PST transformation into less toxic analogs and degradation, both chemically or enzymatically, will be important for the development of methods for the detoxification of contaminated water supplies and of shellfish destined for consumption. Some PSTs also have demonstrated pharmaceutical potential as a long-term anesthetic in the treatment of anal fissures and for chronic tension-type headache. The recent elucidation of the saxitoxin biosynthetic gene cluster in cyanobacteria and the identification of new PST analogs will present opportunities to further explore the pharmaceutical potential of these intriguing alkaloids.

15 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
DWDavid Wylensek
David Wylensek
THThomas Hitch
Thomas Hitch
TRThomas Riedel
Thomas Riedel
AAAfrizal Afrizal
Afrizal Afrizal
NKNeeraj Kumar
Neeraj Kumar
TCThomas Clavel
Thomas Clavel
Our knowledge about the gut microbiota of pigs is still scarce, despite the importance of these animals for biomedical research and agriculture. Here, we present a collection of cultured bacteria from the pig gut, including 110 species across 40 families and nine phyla. We provide taxonomic descriptions for 22 novel species and 16 genera. Meta-analysis of 16S rRNA amplicon sequence data and metagenome-assembled genomes reveal prevalent and pig-specific species within Lactobacillus, Streptococcus, Clostridium, Desulfovibrio, Enterococcus, Fusobacterium, and several new genera described in this study. Potentially interesting functions discovered in these organisms include a fucosyltransferase encoded in the genome of the novel species Clostridium porci, and prevalent gene clusters for biosynthesis of sactipeptide-like peptides. Many strains deconjugate primary bile acids in in vitro assays, and a Clostridium scindens strain produces secondary bile acids via dehydroxylation. In addition, cells of the novel species Bullifex porci are coccoidal or spherical under the culture conditions tested, in contrast with the usual helical shape of other members of the family Spirochaetaceae. The strain collection, called ‘Pig intestinal bacterial collection’ (PiBAC), is publicly available at www.dsmz.de/pibac and opens new avenues for functional studies of the pig gut microbiota.

1 April 2016 in Harmful Algae
Verified
Journal Article
Closed access
LPLeanne A. Pearson
Leanne A. Pearson
EDElke Dittmann
Elke Dittmann
RMRabia Mazmouz
Rabia Mazmouz
SOSarah E. Ongley
Sarah E. Ongley
PDPaul D'Agostino
Paul D'Agostino
BNBrett Neilan
Brett Neilan

1 May 2018 in Metabolic Engineering
Verified
Journal Article
Closed access
CGChristian Greunke
Christian Greunke
EDElke Regina Duell
Elke Regina Duell
PDPaul D'Agostino
Paul D'Agostino
AGAnna Glöckle
Anna Glöckle
KLKatharina Lamm
Katharina Lamm
TGTobias Alexander Marius Gulder
Tobias Alexander Marius Gulder


3 September 2015 in BMC Genomics
Verified
Journal Article
Open access
PDF file
MMMelinda L. Micallef
Melinda L. Micallef
PDPaul D'Agostino
Paul D'Agostino
DSDeepti Sharma
Deepti Sharma
RVRajesh Viswanathan
Rajesh Viswanathan
MMMichelle Moffitt
Michelle Moffitt
Cyanobacteria are well known for the production of a range of secondary metabolites. Whilst recent genome sequencing projects has led to an increase in the number of publically available cyanobacterial genomes, the secondary metabolite potential of many of these organisms remains elusive. Our study focused on the 11 publically available Subsection V cyanobacterial genomes, together with the draft genomes of Westiella intricata UH strain HT-29-1 and Hapalosiphon welwitschii UH strain IC-52-3, for their genetic potential to produce secondary metabolites. The Subsection V cyanobacterial genomes analysed in this study are reported to produce a diverse range of natural products, including the hapalindole-family of compounds, microcystin, hapalosin, mycosporine-like amino acids and hydrocarbons. A putative gene cluster for the cyclic depsipeptide hapalosin, known to reverse P-glycoprotein multiple drug resistance, was identified within three Subsection V cyanobacterial genomes, including the producing cyanobacterium H. welwitschii UH strain IC-52-3. A number of orphan NRPS/PKS gene clusters and ribosomally-synthesised and post translationally-modified peptide gene clusters (including cyanobactin, microviridin and bacteriocin gene clusters) were identified. Furthermore, gene clusters encoding the biosynthesis of mycosporine-like amino acids, scytonemin, hydrocarbons and terpenes were also identified and compared. Genome mining has revealed the diversity, abundance and complex nature of the secondary metabolite potential of the Subsection V cyanobacteria. This bioinformatic study has identified novel biosynthetic enzymes which have not been associated with gene clusters of known classes of natural products, suggesting that these cyanobacteria potentially produce structurally novel secondary metabolites.